Article Sidebar

Submitted
July 18, 2024
Accepted
July 18, 2024
Published
July 18, 2024
Download
PDF
Statistic
Read Counter : 304 Download : 261

Main Article Content

Abstract

Polycystic ovarian syndrome (PCOS) is typical disease characterized through irregular
menstruation as well as the biochemical or clinical signs of an overabundance of testosterone . A
person may experience PCOS symptoms at any age. These include early puberty in infancy, hirsutism
and irregular menstruation in adolescence, infertility and glucose intolerance in middle age and later
in life (heart disease and diabetes mellitus). Although a pelvic ultrasound examination is helpful,
polycystic ovaries are a typical condition in females with PCOS, so ultrasound evidence is required
regarding the diagnosis. It is advisable to test for hyperlipidemia and glucose intolerance, particularly
in obese women, as PCOS is frequently associated with diabetes mellitus. The addition of insulinsensitizing medications, such as metformin, may be helpful in situations like anovulatory infertility.
Lifestyle modifications as advised for diabetes are essential for treatment. While clomiphene citrate
with or without metformin, ovarian drilling, gonadotrophin-induced ovulation induction, and diet and
exercise can all help most women manage their infertility, in vitro fertilization should be avoided. .
The DhiQar governorate served as the study's site. It was collected from Bint Al-Huda Maternity
Hospital comprising 100 blood samples drawn from 30 Healthy lady, and 70 blood samples drawn
from women who had pco and were between the ages of 18 and 42 The hormonal analysis for FSH,
LH , Progesterone and Prolactin by using auto analyzer device maglumi . A device was also used
packed cell volume haematocrite to measure Blood ratio.

Keywords

PCOS FSH LH Progesterone and Prolactin

Article Details

License

Copyright (c) 2024 University of Thi-Qar Journal Of Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the
  2. polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol
  3. Metab 2001; 86: 1626-1632 ..
  4. Badawy, A., & Elnashar, A. (2011). Treatment options for polycystic ovary syndrome. International
  5. journal of women's health, 3, 25
  6. Codner, E., ... & Rudaz, C. G. (2017). An international consortium update .:
  7. Crespo, R. P., Bachega, T. A., Mendonça, B. B., & Gomes, L. G. (2018 An update of genetic basis of
  8. PCOS pathogenesis. Archives of Endocrinology and Metabolism, 62(3), 352-361.
  9. Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of
  10. obesity, in polycystic ovary syndrome. Diabetes 1989; 38 1165 -1174
  11. Dunaif A. Molecular mechanisms of insulin resistance in the polycystic ovary syndrome. Semin
  12. Reprod Endocrinol 1994; 12: 15-20
  13. dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab 2002:B7: 5702-5705
  14. Emekci Ozay, O., Ozay, A. C., Acar, B., Cagliyan, E., Seçil, M., & Küme, T. (2016). Role of
  15. kisspeptin in polycystic ovary syndrome (PCOS). Gynecological Endocrinology, 32(9), 7187-22 ..
  16. Farquhar C, Vandekerckhove P, Lilford R. Laparoscopic “drilling” by diathermy or laser for
  17. ovulation induction in anovulatory polycystic ovary syndrome (Cochrane Review). The Cochrane
  18. Library, Issue 2, 2003. Oxford: Update Software..
  19. Farquhar CM, Birdsall M, Manning P, et al. The prevalence of polycystic ovaries on ultrasound
  20. scanning in a population of randomly selected women. Aust N Z J Obstet Gynaecol 1994; 34: 67-72.
  21. Fassnacht, M., Schlenz, N., Schneider, S. B., Wudy, S. A., Allolio, BArlt, W. (2003). Beyond
  22. adrenal and ovarian androgen generation: increased peripheral 5α-reductase activity in women with
  23. polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 88(6), 2760-2766.
  24. Group. (2004). Revised 2003 consensus on diagnostic criteria and long‐term
  25. Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrialcarcinoma. Lancet
  26. ; 361: 1810-1812.
  27. Ibanez L, Potau N, Ferrer A, et al. Anovulation in eumenorrheic, nonobese adolescent girls born
  28. small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and
  29. reduces abdominal fat excess .,
  30. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazonerosiglitazone,
  31. pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003;
  32. (3): CD003053.
  33. Pasquali, R., Gambineri, A., & Pagotto, U. (2006). The impact of obesity on reproduction in women
  34. with polycystic ovary syndrome. BJOG: An International Journal of Obstetrics & Gynaecology,
  35. (10), 1148-1159..
  36. Norman RJ, Kidson WJ, Cuneo RC, et al. Metformin and intervention in polycystic ovary syndrome.
  37. Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric
  38. Endocrine Group. Med J Aust 2001; 174: 580-583.
  39. Norman RJ, Masters L, Milner CR, et al. Relative risk of conversion from normoglycaemia to
  40. impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian
  41. syndrome. Hum Reprod 2001; 16: 1995-1998.
  42. Norman RJ. Hyperandrogenaemia and the ovary. Mol Cell Endocrinol 2002; 191:113-119
  43. adolescence. Hormone research in paediatrics, 88, 371-395.
  44. Quinn, M., Shinkai, K., Pasch, L., Kuzmich, L., Cedars, M Huddleston, H. (2014). Prevalence of
  45. androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated
  46. clinical and biochemical features. Fertility and sterility, 101(4), 1129-1134.
  47. Recabarren, S. E., Smith, R., Rios, R., Maliqueo, M., Echiburu, B Codner, E., ... & Sir-Petermann,
  48. T. (2008). Metabolic profile in sons of women with polycystic ovary syndrome. The Journal of
  49. Clinical Endocrinology & Metabolism, 93(5), 1820-1826.
  50. Rotteram ESH E/ S M‐Sponsore COS Consensus Workshop reproduction, 19(1), 41-47.
  51. Sirmans, S. M., & pate, K. A. (2014). Epidemiology, diagnosis, and management of polycystic
  52. ovary syndrome. Clinical epidemiology, 6, 1..
  53. Tarrade A, Schoonjans K, Pavan L, etal. PPARgamma/RXRalpha heterodimers control human
  54. trophoblast invasion. J Clin Endocrinol Metab 2001; 86: 5017-5024.
  55. Valkenburg, O., Steegers-Theunissen, R. P., Smedts, H. P., Dallinga-Thie G. M., Fauser, B. C.,
  56. Westerveld, E. H., & Laven, J. S. (2008). A more atherogenic serum lipoprotein profile is present in
  57. women with polycystic ovary syndrome: a case-control study. The Journal Of Clinical Endocrinology
  58. Metabolism, 93(2), 470-476..
  59. Wild S, Pierpoint T, McKeigue P, et al. Cardiovascular disease in women with polycystic ovary
  60. syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52:

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)